Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

mRNA cancer immunotherapies

- PMLiVE

NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

More than 11,000 people are diagnosed with head and neck cancers every year in England

- PMLiVE

UK government publishes 10 Year Health Plan for England to ‘reinvent’ NHS

The plan’s three overarching themes are hospital to community, analogue to digital and sickness to prevention

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

- PMLiVE

BioNTech announces £1bn UK investment to boost regional R&D presence

The UK government has also agreed to award the company a grant of up to £129m

- PMLiVE

UK government’s AMR study highlights importance of appropriate antibiotic use

The UKHSA found that some bacteria are already becoming resistant to ceftazidime/avibactam

- PMLiVE

Prime minister unveils UK government’s plans to abolish NHS England

The move aims to cut waiting times and free up money for front-line services

- PMLiVE

UK government launches ‘landmark’ AI breast cancer screening trial

Approximately 55,000 cases of the disease are diagnosed every year in the UK

- PMLiVE

UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance

The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year

- PMLiVE

Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

The updated vaccine was shown to generate an improved response against currently circulating variants

- PMLiVE

UK government launches £400m investment programme to support clinical research

Up to 18 clinical trial hubs will be created to accelerate the development of new drugs

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links